Benzyldihydroxyoctenone, a novel anticancer agent, induces apoptosis via mitochondrial-mediated pathway in androgen-sensitive LNCaP prostate cancer cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moon, Hong Sang | - |
dc.contributor.author | Lim, Haeyoung | - |
dc.contributor.author | Moon, Sangik | - |
dc.contributor.author | Oh, Ha Lim | - |
dc.contributor.author | Kim, Young-Tae | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Lee, Chul-Hoon | - |
dc.date.accessioned | 2022-04-01T09:21:42Z | - |
dc.date.available | 2022-04-01T09:21:42Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2009-02 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/136094 | - |
dc.description.abstract | This study was aimed to evaluate detailed mechanisms on the apoptotic induction of benzyldihydroxyoctenone, a novel compound isolated from Streptomyces sp. KACC91015, in androgen-sensitive LNCaP prostate cancer cells. Benzyldihydroxyoctenone, designated as F3-2-5 in the current study, caused accumulation of apoptotic sub-G1 phase in the flow cytometric analysis using propidium iodide staining. Moreover, the typical apoptotic DNA fragmentation of the LNCaP cells treated with 30 mu M of F3-2-5 was confirmed using the TUNEL assay. This apoptotic induction of F3-2-5 in the LNCaP cells was associated with the cytochrome c release from mitochondria to cytosol, and the activation of procaspase-8, -9, and -3, as well as the specific proteolytic cleavage of poly(ADP-ribose) polymerase (PARP). In addition, F3-2-5 treatment caused the down-regulation of the antiapoptotic protein, such as Bcl-2 and Bcl-X-L, but the proapoptotic protein, such as Bax, was not influenced. To investigate whether apoptotic induction by F3-2-5 is also due to the down- regulation of androgen receptor (AR), Western blot analysis and quantitative RT-PCR were conducted in F3-2-5-treated LNCaP prostate cancer cells. We found that F3-2-5 significantly inhibited the expression levels of AR and prostate-specific antigen (PSA) proteins in a time-dependent manner, as well as F3-2-5 abrogated the up-regulation of AR and PSA genes with and without DHT. Therefore, F3-2-5 has been shown to be an androgen antagonist, suggesting that F3-2-5 could be a potent agent for the treatment of both androgen-dependent and hormone-refractory prostate cancer. (C) 2008 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | Benzyldihydroxyoctenone, a novel anticancer agent, induces apoptosis via mitochondrial-mediated pathway in androgen-sensitive LNCaP prostate cancer cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Moon, Hong Sang | - |
dc.contributor.affiliatedAuthor | Lee, Chul-Hoon | - |
dc.identifier.doi | 10.1016/j.bmcl.2008.12.029 | - |
dc.identifier.scopusid | 2-s2.0-58549091063 | - |
dc.identifier.wosid | 000262707000036 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.19, no.3, pp.742 - 744 | - |
dc.relation.isPartOf | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 19 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 742 | - |
dc.citation.endPage | 744 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Benzyldihydroxyoctenone | - |
dc.subject.keywordAuthor | LNCaP cells | - |
dc.subject.keywordAuthor | Apoptosis | - |
dc.subject.keywordAuthor | Prostate cancer | - |
dc.subject.keywordAuthor | Androgen receptor | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0960894X08015412?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.